Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy
This study represents a proof-of-principle to identify potential checkpoint therapy responders in advance at the time of diagnosis. The work was based on a scoring derived from a multiplexed marker profiling. However, larger patient cohorts need to be prospectively evaluated for further validation.
Authors
- Anja K. Wege (ORCID: https://orcid.org/0000-0002-8838-0532)
- Christina Bruß
- Olaf Ortmann (ORCID: https://orcid.org/0000-0001-6238-3949)
- Madeleine Hetterich
- Verena Schweihofer
- Gunther Glehr (ORCID: https://orcid.org/0000-0002-1495-9162)
- Maria Hatzipanagiotou
- Florian Weber (ORCID: https://orcid.org/0000-0001-7480-8828)
- Gero Brockhoff (ORCID: https://orcid.org/0000-0001-8398-8349)
- Richard J. Bauer
- Miriam Fernández-Pacheco Álvarez
- Stephan Seitz
Institutions
- University Hospital Regensburg (DE)
- University of Regensburg (DE)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1186/s12935-025-03729-7
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Universität Regensburg